Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2023-506906-38-00 | Other Identifier | EU CT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AbbVie | INDUSTRY |
Not provided
Not provided
Not provided
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed.
Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participants with previously untreated FL will be enrolled in approximately 250 sites across the world.
Participants will receive R2 (intravenous [IV] infusion of rituximab (R) and oral capsules of lenalidomide) alone or in combination with subcutaneous injections of epcoritamab. Participants may also receive investigator's choice chemoimmunotherapy (CIT): IV infusion of obinutuzumab (G) and IV injections of cyclophosphamide, IV injections of doxorubicin, IV injections of vincristine, oral tablets of prednisone (CHOP) [G-CHOP]/ R-CHOP or G and IV infusion of bendamustine (Benda) [G-Benda]/R-Benda. The total treatment duration will be 120 weeks for all arms except A2, which is 24 weeks of treatment.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm A1: Epcoritamab + Lenalidomide and Rituximab (R2) | Experimental | Participants will receive epcoritamab in combination with R2 (ER2), followed by epcoritamab during the 120 week treatment duration. |
|
| Arm A2: Epcoritamab + Lenalidomide and Rituximab (R2) | Experimental | Participants will receive epcoritamab in combination with R2 (ER2), during the 24 week treatment duration. |
|
| Arm B: Chemoimmunotherapy (CIT) Option A | Experimental | Participants will receive CIT Option A (obinutuzumab (G) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) [G-CHOP]/ rituximab (R)-CHOP during the 120 week treatment duration. |
|
| Arm B: Chemoimmunotherapy (CIT) Option B | Experimental | Participants will receive CIT Option B (G and bendamustine (Benda) [G-Benda]/R-Benda during the 120 week treatment duration. |
|
| Arm C: Lenalidomide and Rituximab (R2) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Epcoritamab | Drug | Subcutaneous (SC) Injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Arm A1 vs Arm B: Percentage of Participants who Achieve Complete Response rate at 30 months (CR30) | CR30 will be determined by positron emission tomography-computerized tomography (cat scan) [PET-CT] per Lugano 2014 criteria, as assessed by independent review committee (IRC). | Up to 30 Months |
| Arm A1 vs Arm B: Number of Participants with Progression-free survival (PFS) | PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first. | Up to 10 Years |
| Measure | Description | Time Frame |
|---|---|---|
| Arm A1 vs Arm B: Overall Survival (OS) | OS is defined as the time from the date of randomization to the date of death of any cause. | Up to 10 Years |
| Arm A1 vs Arm B: Rate of Minimal Residual Disease (MRD) Negativity Rate |
Not provided
Inclusion Criteria:
Diagnosis of follicular lymphoma (FL).
Have CD20+, histologically confirmed classic FL (previously Grade 1 to 3a FL) at most recent representative tumor biopsy based on the local pathology report, according to the 5th edition of World Health Organization (WHO) Classification of Haematolymphoid Tumours.
Are willing and able to comply with procedures required in the protocol.
Must have stage, III, IV or II with bulky disease >= 7cm).
Must be in need of systemic treatment per investigator, as evidenced by meeting at least one of the Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.
Has one or more target lesions:
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Able to receive at least one of the standard of care chemoimmunotherapy (CIT) treatment regimens: [Arm B] at the discretion of the Investigator, and rituximab and lenalidomide (R2) [Arm C].
Have laboratory values meeting the criteria in the protocol.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| ABBVIE CALL CENTER | Contact | 844-663-3742 | abbvieclinicaltrials@abbvie.com |
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCSF Fresno /ID# 264712 | Recruiting | Fresno | California | 93701-2302 | United States | |
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Experimental |
Participants will receive lenalidomide and rituximab (R2) during the 120 week treatment duration. |
|
|
| Prednisone | Drug | Oral Tablet |
|
| Rituximab | Drug | Intravenous (IV) Infusion |
|
| Lenalidomide | Drug | Oral Capsule |
|
| Doxorubicin | Drug | IV Injection |
|
| Vincristine | Drug | IV Injection |
|
| Cyclophosphamide | Drug | IV Injection |
|
| Obinutuzumab | Drug | IV Infusion |
|
| Bendamustine | Drug | IV Infusion |
|
MRD negativity rate, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with follicular lymphoma (FL) MRD at baseline.
| Up to 10 Years |
| Arm A1 vs Arm B: Change from Baseline in Physical Functioning (PF) According to European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer (EORTC QLQ-C30) | The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning. | 21 Weeks |
| Arm A1 vs Arm A2: Percentage of Participants who Achieve CR30 | CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC. | Up to 30 Months |
| Arm A1 vs Arm C: Percentage of Participants who Achieve CR30 | CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC. | Up to 30 Months |
| Arm A1 vs Arm A2: Number of Participants with PFS | PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first. | Up to 10 Years |
| Arm A1 vs Arm C: Number of Participants with PFS | PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per IRC, or death, whichever occurs first. | Up to 10 Years |
| Arm A1 vs Arm A2: Rate of MRD Negativity | MRD negativity, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with FL MRD at baseline. | Up to 10 Years |
| Arm A1 vs Arm C: Rate of MRD Negativity | MRD negativity, defined as the absence of tumor specific molecules in whole blood and/or bone marrow in participants with FL MRD at baseline. | Up to 10 Years |
| Arm A1 vs Arm A2: Change from Baseline in PF According to EORTC QLQ-C30 | The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning. | Up to 10 Years |
| Arm A1 vs Arm C: Change from Baseline in PF According to EORTC QLQ-C30 | The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning. | Up to 10 Years |
| Arm A1 vs Arm A2: OS | OS is defined as the time from the date of randomization to the date of death of any cause. | Up to 10 Years |
| Arm A1 vs Arm C: OS | OS is defined as the time from the date of randomization to the date of death of any cause. | Up to 10 Years |
| Arm A1 vs Arm A2: Percentage of Participants who Achieve CR30 | CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator. | Up to 30 Months |
| Arm A1 vs Arm B: Percentage of Participants who Achieve CR30 | CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator. | Up to 30 Months |
| Arm A1 vs Arm C: Percentage of Participants who Achieve CR30 | CR30 will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator. | Up to 30 Months |
| Arm A1 vs Arm A2: Number of Participants with PFS | PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first. | Up to 10 Years |
| Arm A1 vs Arm B: Number of Participants with PFS | PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first. | Up to 10 Years |
| Arm A1 vs Arm C: Number of Participants with PFS | PFS is defined as the time from randomization until disease progression determined by Lugano 2014 criteria per investigator, or death, whichever occurs first. | Up to 10 Years |
| Arm A1 vs Arm A2: Percentage of Participants with Change in CR Rate per IRC | CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC. | Up to 10 Years |
| Arm A1 vs Arm A2: Percentage of Participants with Change in CR Rate per Investigator | CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator. | Up to 10 Years |
| Arm A1 vs Arm B: Percentage of Participants with Change in CR Rate per IRC | CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC. | Up to 10 Years |
| Arm A1 vs Arm B: Percentage of Participants with Change in CR Rate per Investigator | CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator. | Up to 10 Years |
| Arm A1 vs Arm C: Percentage of Participants with Change in CR Rate per IRC | CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by IRC. | Up to 10 Years |
| Arm A1 vs Arm C: Percentage of Participants with Change in CR Rate per Investigator | CR will be determined by PET-CT per Lugano 2014 criteria, as assessed by investigator. | Up to 10 Years |
| Arm A1 vs Arm A2: Number of Participants with Best Overall Response (BOR) per per Investigator | BOR is defined as the percentage of participants who achieve CR or partial response (PR) determined by Lugano 2014 criteria as assessed by investigator, or death from any cause. | Up to 10 Years |
| Arm A1 vs Arm A2: Number of Participants with BOR per IRC | BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause. | Up to 10 Years |
| Arm A1 vs Arm B: Number of Participants with BOR per Investigator | BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by investigator, or death from any cause. | Up to 10 Years |
| Arm A1 vs Arm B: Number of Participants with BOR per IRC | BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause. | Up to 10 Years |
| Arm A1 vs Arm C: Number of Participants with BOR per Investigator | BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by investigator, or death from any cause. | Up to 10 Years |
| Arm A1 vs Arm C: Number of Participants with BOR per IRC | BOR is defined as the percentage of participants who achieve CR or PR determined by Lugano 2014 criteria as assessed by IRC, or death from any cause. | Up to 10 Years |
| Arm A1 vs Arm A2: Number of Participants with Event-free Survival (EFS) per IRC | EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first. | Up to 10 Years |
| Arm A1 vs Arm A2: Number of Participants with EFS per Investigator | EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first. | Up to 10 Years |
| Arm A1 vs Arm B: Number of Participants with EFS per IRC | EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first. | Up to 10 Years |
| Arm A1 vs Arm B: Number of Participants with EFS per Investigator | EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first. | Up to 10 Years |
| Arm A1 vs Arm C: Number of Participants with EFS per IRC | EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per IRC, or death, whichever occurs first. | Up to 10 Years |
| Arm A1 vs Arm C: Number of Participants with EFS per Investigator | EFS is defined as the time from randomization until adverse event determined by Lugano 2014 criteria per investigator, or death, whichever occurs first. | Up to 10 Years |
| Arm A1 vs Arm A2: Duration of Response (DOR) per IRC | DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC. | Up to 10 Years |
| Arm A1 vs Arm A2: DOR per Investigator | DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator. | Up to 10 Years |
| Arm A1 vs Arm B: DOR per IRC | DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC. | Up to 10 Years |
| Arm A1 vs Arm B: DOR per Investigator | DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator. | Up to 10 Years |
| Arm A1 vs Arm C: DOR per IRC | DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by IRC. | Up to 10 Years |
| Arm A1 vs Arm C: DOR per Investigator | DOR is defined as the time from PR or CR to disease progression per Lugano 2014 criteria, as assessed by investigator. | Up to 10 Years |
| Arm A1 vs Arm A2: Duration of Complete Response (DOCR) per IRC | DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC. | Up to 10 Years |
| Arm A1 vs Arm A2: DOCR per Investigator | DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator. | Up to 10 Years |
| Arm A1 vs Arm B: DOCR per IRC | DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC. | Up to 10 Years |
| Arm A1 vs Arm B: DOCR per Investigator | DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator. | Up to 10 Years |
| Arm A1 vs Arm C: DOCR per IRC | DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by IRC. | Up to 10 Years |
| Arm A1 vs Arm C: DOCR per Investigator | DOCR is defined as the time from CR to disease progression per Lugano 2014 criteria, as assessed by investigator. | Up to 10 Years |
| Arm A1 vs Arm A2: Time to Next Anti-lymphoma Therapy (TTNT) per Investigator | TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy. | Up to 10 Years |
| Arm A1 vs Arm A2: TTNT per IRC | TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy. | Up to 10 Years |
| Arm A1 vs Arm A2: TTNT per Investigator | TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy. | Up to 10 Years |
| Arm A1 vs Arm B: TTNT per IRC | TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy. | Up to 10 Years |
| Arm A1 vs Arm B: TTNT per Investigator | TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy. | Up to 10 Years |
| Arm A1 vs Arm C: TTNT per IRC | TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy. | Up to 10 Years |
| Arm A1 vs Arm C: TTNT per Investigator | TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy. | Up to 10 Years |
| Arm A1 vs Arm A2: Time to Progression per IRC | Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC. | Up to 10 Years |
| Arm A1 vs Arm A2: Time to Progression per Investigator | Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator. | Up to 10 Years |
| Arm A1 vs Arm B: Time to Progression per IRC | Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC. | Up to 10 Years |
| Arm A1 vs Arm B: Time to Progression per Investigator | Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator. | Up to 10 Years |
| Arm A1 vs Arm C: Time to Progression per IRC | Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by IRC. | Up to 10 Years |
| Arm A1 vs Arm C: Time to Progression per Investigator | Time to progression defined as the time from randomization to disease progression per Lugano 2014 criteria, as assessed by investigator. | Up to 10 Years |
| Arm A1 vs Arm A2: Number of Participants with Progression-free Survival After Subsequent Anti-Lymphoma Therapy (PFS2) | PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause. | Up to 10 Years |
| Arm A1 vs Arm B: Number of Participants with PFS2 | PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause. | Up to 10 Years |
| Arm A1 vs Arm C: Number of Participants with PFS2 | PFS2 is defined as the time after subsequent anti-lymphoma therapy to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause. | Up to 10 Years |
| Arm A1 vs Arm A2: Change in Tolerability as Measured by Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) | The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence. | Up to 10 Years |
| Arm A1 vs Arm B: Change in Tolerability as Measured by PRO-CTCAE | The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence. | Up to 10 Years |
| Arm A1 vs Arm C: Change in Tolerability as Measured by PRO-CTCAE | The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence. | Up to 10 Years |
| Arm A1 vs Arm A2: Change in Tolerability as Measured by The Functional Assessment of Cancer Therapy - General (FACT-G) Item GP5 | The functional assessment of cancer therapy singly item - GP5 (FACT-GP5) is a single question asking if participant is bothered by side effects of treatment. | Up to 10 Years |
| Arm A1 vs Arm B: Change in Tolerability as Measured by FACT-G Item GP5 | The FACT-GP5 is a single question asking if participant is bothered by side effects of treatment. | Up to 10 Years |
| Arm A1 vs Arm C: Change in Tolerability as Measured by FACT-GG Item GP5 | The FACT-GP5 is a single question asking if participant is bothered by side effects of treatment. | Up to 10 Years |
| Arm A1 vs Arm A2: Change in Symptoms as Measured by The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) | The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale. | Up to 10 Years |
| Arm A1 vs Arm B: Change in Symptoms as Measured by FACT-Lym | The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale. | Up to 10 Years |
| Arm A1 vs Arm C: Change in Symptoms as Measured by FACT-Lym | The objective of the FACT-Lym patient reported outcome (PRO) is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale. | Up to 10 Years |
| Arm A1 vs Arm A2: Change in Quality of Life (QoL) as Measured by FACT-Lym | The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale. | Up to 10 Years |
| Arm A1 vs Arm B: Change in QoL as Measured by FACT-Lym | The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale. | Up to 10 Years |
| Arm A1 vs Arm C: Change in QoL as Measured by FACT-Lym | The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale. | Up to 10 Years |
| Arm A1 vs Arm A2: Time-to-first PRO deterioration (TTD) in well-being using the lymphoma subscale (LymS) of FACT-Lym | The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale. | Up to 10 Years |
| Arm A1 vs Arm B: TTD in well-being using LymS of FACT-Lym | The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale. | Up to 10 Years |
| Arm A1 vs Arm C: TTD in well-being using LymS of FACT-Lym | The objective of the FACT-Lym PRO is to assess health-related quality of life issues for adult lymphoma patients. It utilizes a 5-point Likert-type scale. | Up to 10 Years |
| Arm A1 vs Arm A2: Change in QoL as Measured by 5-Level European Quality of Life (EuroQol)-5-dimension [EQ-5D-5L] | The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state. | Up to 10 Years |
| Arm A1 vs Arm B: Change in QoL as Measured by EQ-5D-5L | The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state. | Up to 10 Years |
| Arm A1 vs Arm C: Change in QoL as Measured by EQ-5D-5L | The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state. | Up to 10 Years |
| Arm A1 vs Arm A2: TTD in PF using the QLQ-C30 Physical Functioning Scale | The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning. | Up to 10 Years |
| Arm A1 vs Arm B: TTD in PF using the QLQ-C30 Physical Functioning Scale | The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning. | Up to 10 Years |
| Arm A1 vs Arm C: TTD in PF using the QLQ-C30 Physical Functioning Scale | The PF of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indication worse functioning. | Up to 10 Years |
| Arm A1 vs Arm A2: Change from baseline in the remaining items and domains of the EORTC QLQ-C30 | The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life. | Up to 10 Years |
| Arm A1 vs Arm B: Change from baseline in the remaining items and domains of the EORTC QLQ-C30 | The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life. | Up to 10 Years |
| Arm A1 vs Arm C: Change from baseline in the remaining items and domains of the EORTC QLQ-C30 | The EORTC QLQ-C30: A 30 items questionnaire to assess the quality of life of cancer patients on physical, emotional, cognitive, and social functions and symptoms. with a higher score indication worse quality of life. | Up to 10 Years |
| Arm A1 vs Arm A2: Change in Patient Global Impression of Change (PGIC) for General Lymphoma Symptoms | The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. | Up to 10 Years |
| Arm A1 vs Arm C: Change in PGIC for General Lymphoma Symptoms | The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. | Up to 10 Years |
| Arm A1 vs Arm A2: Change in Patient Global Impression of Severity (PGIS) for General Lymphoma Symptoms | The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity. | Up to 10 Years |
| Arm A1 vs Arm B: Change in PGIS for General Lymphoma Symptoms | The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity. | Up to 10 Years |
| Arm A1 vs Arm C: Change in PGIS for General Lymphoma Symptoms | The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity. | Up to 10 Years |
| Scripps Mercy Hospital /ID# 265393 |
| Recruiting |
| San Diego |
| California |
| 92103 |
| United States |
| Sansum Clinic Research /ID# 261596 | Recruiting | Santa Barbara | California | 93105 | United States |
| Rocky Mountain Cancer Centers - Boulder /ID# 261203 | Active, not recruiting | Boulder | Colorado | 80303 | United States |
| Christiana Care Health Service /ID# 261207 | Recruiting | Newark | Delaware | 19713 | United States |
| Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 262445 | Active, not recruiting | Jacksonville | Florida | 32256 | United States |
| Advent Health /ID# 261578 | Recruiting | Orlando | Florida | 32803 | United States |
| Orlando Health Cancer Institute /ID# 260983 | Active, not recruiting | Orlando | Florida | 32806 | United States |
| Moffitt Cancer Center /ID# 259487 | Recruiting | Tampa | Florida | 33612-9416 | United States |
| Beacon Cancer Care - Coeur d'Alene /ID# 260670 | Recruiting | Coeur d'Alene | Idaho | 83814 | United States |
| Northwestern Medicine - Northwestern Memorial Hospital /ID# 259814 | Recruiting | Chicago | Illinois | 60611 | United States |
| Cancer Care Specialists Of Central Illinois /ID# 272464 | Recruiting | Decatur | Illinois | 62526 | United States |
| Loyola University /ID# 259462 | Completed | Maywood | Illinois | 60153 | United States |
| Illinois Cancer Care, PC /ID# 261526 | Recruiting | Peoria | Illinois | 61615 | United States |
| Fort Wayne Medical Oncology and Hematology- South Office /ID# 259583 | Recruiting | Fort Wayne | Indiana | 46804 | United States |
| University of Iowa Health Care /ID# 262132 | Recruiting | Des Moines | Iowa | 50314-3017 | United States |
| University of Louisville Hospital /ID# 260544 | Recruiting | Louisville | Kentucky | 40202 | United States |
| Norton Cancer Institute - St. Matthews /ID# 261076 | Recruiting | Louisville | Kentucky | 40207 | United States |
| New England Cancer Specialists - Westbrook /ID# 260672 | Recruiting | Westbrook | Maine | 04092 | United States |
| University of Maryland, Baltimore /ID# 259538 | Recruiting | Baltimore | Maryland | 21201 | United States |
| Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 259476 | Recruiting | Bethesda | Maryland | 20817 | United States |
| St. Luke's Hospital - Chesterfield /ID# 260489 | Active, not recruiting | Chesterfield | Missouri | 63017 | United States |
| Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 260006 | Completed | Billings | Montana | 59102 | United States |
| Nebraska Cancer Specialists (NCS) - Regional Cancer Center - St Francis Location /ID# 262506 | Recruiting | Grand Island | Nebraska | 68803 | United States |
| Nebraska Hematology-Oncology /ID# 269692 | Recruiting | Lincoln | Nebraska | 68506 | United States |
| Nebraska Cancer Specialists - Omaha - Wright Street /ID# 262505 | Recruiting | Omaha | Nebraska | 68130 | United States |
| University of Nebraska Medical Center /ID# 261996 | Recruiting | Omaha | Nebraska | 68198 | United States |
| University of New Mexico /ID# 261083 | Completed | Albuquerque | New Mexico | 87102-4517 | United States |
| Presbyterian Kaseman Hospital /ID# 262451 | Completed | Albuquerque | New Mexico | 87110 | United States |
| Presbyterian Rust Medical Center /ID# 262447 | Completed | Rio Rancho | New Mexico | 87124 | United States |
| New York Oncology Hematology - Albany Cancer Center /ID# 261814 | Completed | Albany | New York | 12206-5013 | United States |
| NYU Langone Hospital - Long Island /ID# 265531 | Recruiting | Mineola | New York | 11501 | United States |
| NYU Langone Medical Center /ID# 264518 | Recruiting | New York | New York | 10016-6402 | United States |
| Icahn School of Medicine at Mount Sinai /ID# 259595 | Recruiting | New York | New York | 10029 | United States |
| New York Oncology Hematology /ID# 270208 | Recruiting | Troy | New York | 12180 | United States |
| Clinical Research Alliance - Westbury /ID# 261078 | Recruiting | Westbury | New York | 11590 | United States |
| Novant Health Presbyterian Medical Center /ID# 259740 | Active, not recruiting | Charlotte | North Carolina | 28204 | United States |
| Novant Health Forsyth Medical Center /ID# 259741 | Active, not recruiting | Winston-Salem | North Carolina | 27103 | United States |
| Oncology Hematology Care, Inc - Blue Ash /ID# 261204 | Completed | Cincinnati | Ohio | 45252 | United States |
| Taylor Cancer Research Center /ID# 260488 | Completed | Maumee | Ohio | 43537-1921 | United States |
| Oncology Associates of Oregon, P.C. /ID# 261816 | Recruiting | Eugene | Oregon | 97401 | United States |
| MUSC Hollings Cancer Center /ID# 259604 | Active, not recruiting | Charleston | South Carolina | 29425 | United States |
| Prisma Health /ID# 259602 | Active, not recruiting | Greenville | South Carolina | 29605 | United States |
| Sarah Cannon Research Institute - Tristar Centennial Medical Center /ID# 274985 | Recruiting | Nashville | Tennessee | 37203 | United States |
| Texas Oncology - Austin Midtown /ID# 261208 | Active, not recruiting | Austin | Texas | 78705 | United States |
| Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 261206 | Active, not recruiting | Dallas | Texas | 75246-2003 | United States |
| MD Anderson Cancer Center /ID# 260984 | Active, not recruiting | Houston | Texas | 77030-4000 | United States |
| Oncology Consultants /ID# 268390 | Active, not recruiting | Houston | Texas | 77030 | United States |
| Joe Arrington Cancer Research /ID# 260382 | Active, not recruiting | Lubbock | Texas | 79410 | United States |
| Intermountain Healthcare LDS Hospital /ID# 259759 | Active, not recruiting | Salt Lake City | Utah | 84143 | United States |
| Virginia Cancer Specialists - Fairfax /ID# 261205 | Recruiting | Fairfax | Virginia | 22031 | United States |
| Oncology and Hematology Associates of Southwest Virginia /ID# 261592 | Recruiting | Roanoke | Virginia | 98684 | United States |
| Swedish Cancer Institute - Edmonds /ID# 266356 | Active, not recruiting | Edmonds | Washington | 98026 | United States |
| Swedish Cancer Institute - Issaquah /ID# 266358 | Completed | Issaquah | Washington | 98029 | United States |
| Vista Oncology - East Olympia /ID# 261360 | Recruiting | Olympia | Washington | 98506-5028 | United States |
| Virginia Mason Hospital and Medical Center /ID# 260549 | Active, not recruiting | Seattle | Washington | 98101 | United States |
| Swedish Medical Center - Seattle /ID# 260370 | Completed | Seattle | Washington | 98104 | United States |
| Northwest Medical Specialties - Tacoma /ID# 262133 | Recruiting | Tacoma | Washington | 98405 | United States |
| Royal Prince Alfred Hospital /ID# 259320 | Recruiting | Camperdown | New South Wales | 2050 | Australia |
| Liverpool Hospital /ID# 259321 | Active, not recruiting | Liverpool | New South Wales | 2170 | Australia |
| Peter MacCallum Cancer Center /ID# 260431 | Active, not recruiting | Melbourne | New South Wales | 3000 | Australia |
| Westmead Hospital /ID# 261465 | Active, not recruiting | Westmead | New South Wales | 2145 | Australia |
| Townsville University Hospital /ID# 259323 | Recruiting | Douglas | Queensland | 4814 | Australia |
| Royal Brisbane and Women's Hospital /ID# 259326 | Recruiting | Herston | Queensland | 4029 | Australia |
| Princess Alexandra Hospital - Woolloongabba /ID# 259329 | Recruiting | Woolloongabba | Queensland | 4102 | Australia |
| Peninsula Private Hospital /ID# 259325 | Recruiting | Frankston | Victoria | 3199 | Australia |
| Fiona Stanley Hospital /ID# 259324 | Recruiting | Murdoch | Western Australia | 6150 | Australia |
| Royal Perth Hospital /ID# 259319 | Recruiting | Perth | Western Australia | 6000 | Australia |
| Algemeen Ziekenhuis klina /ID# 260324 | Recruiting | Brasschaat | Antwerpen | 2930 | Belgium |
| Uza /Id# 260319 | Recruiting | Edegem | Antwerpen | 2650 | Belgium |
| Cliniques Universitaires UCL Saint-Luc /ID# 260311 | Recruiting | Brussels | Brussels Capital | 1200 | Belgium |
| Groupe Sante CHC - Clinique du MontLegia /ID# 260325 | Completed | Liège | Liege | 4000 | Belgium |
| UZ Gent /ID# 260312 | Recruiting | Ghent | Oost-Vlaanderen | 9000 | Belgium |
| Universitair Ziekenhuis Leuven /ID# 260304 | Recruiting | Leuven | Vlaams-Brabant | 3000 | Belgium |
| AZ-Delta. /ID# 260313 | Recruiting | Roeselare | West-Vlaanderen | 8800 | Belgium |
| DF Star /ID# 260844 | Active, not recruiting | Brasília | Federal District | 70390-140 | Brazil |
| Oncocentro de Minas Gerais /ID# 260973 | Active, not recruiting | Belo Horizonte | Minas Gerais | 30360-680 | Brazil |
| Hospital Erasto Gaertner /ID# 260871 | Active, not recruiting | Curitiba | Puerto Rico | 81520-060 | Brazil |
| Hospital Amaral Carvalho - Fundacao Doutor Amaral Carvalho /ID# 260828 | Active, not recruiting | Jaú | São Paulo | 17210-070 | Brazil |
| Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto /ID# 260843 | Active, not recruiting | Ribeirão Preto | São Paulo | 14049-900 | Brazil |
| Fundacao Antonio Prudente - AC Camargo Cancer Center /ID# 260827 | Active, not recruiting | São Paulo | São Paulo | 01509-900 | Brazil |
| Grupo Oncoclínicas Botafogo /ID# 260870 | Active, not recruiting | Rio de Janeiro | 22250-905 | Brazil |
| Real e Benemérita Associação Portuguesa de Beneficência /ID# 260826 | Active, not recruiting | São Paulo | 01323-001 | Brazil |
| Instituto D'Or de Pesquisa e Ensino - Regional Sao Paulo /ID# 260829 | Active, not recruiting | São Paulo | 01401-002 | Brazil |
| Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 260822 | Active, not recruiting | São Paulo | 05403-000 | Brazil |
| UMHAT Dr Georgi Stranski EAD /ID# 260763 | Completed | Pleven | 5800 | Bulgaria |
| Acibadem City Clinic Tokuda University Hospital EAD /ID# 260685 | Completed | Sofia | 1407 | Bulgaria |
| UMHAT Sveti Ivan Rilski /ID# 259277 | Completed | Sofia | 1431 | Bulgaria |
| SHAT Hematologic Diseases /ID# 260457 | Active, not recruiting | Sofia | 1797 | Bulgaria |
| Victoria Hospital /ID# 260770 | Recruiting | London | Ontario | N6A 4L6 | Canada |
| The Ottawa Hospital - General Campus /ID# 264470 | Recruiting | Ottawa | Ontario | K1H 8L6 | Canada |
| CSSS Alphonse-Desjardins, CHAU de Levis /ID# 260527 | Recruiting | Lévis | Quebec | G6V 3Z1 | Canada |
| Centre Hospitalier de l'Universite de Montreal (CHUM) /ID# 260617 | Recruiting | Montreal | Quebec | H2X 0C1 | Canada |
| Disc_Royal Victoria Hospital / McGill University Health Centre /ID# 261075 | Recruiting | Montreal | Quebec | H4A 3J1 | Canada |
| Peking University First Hospital /ID# 259816 | Completed | Beijing | Beijing Municipality | 100034 | China |
| Peking University Third Hospital /ID# 259806 | Recruiting | Beijing | Beijing Municipality | 100191 | China |
| The First Affiliated Hospital of Xiamen University /ID# 260014 | Active, not recruiting | Xiamen | Fujian | 361003 | China |
| Sun Yat-Sen University Cancer Center /ID# 260478 | Active, not recruiting | Guangzhou | Guangdong | 510060 | China |
| Guangdong Provincial Peoples Hospital /ID# 260446 | Recruiting | Guangzhou | Guangdong | 510080 | China |
| Zhujiang Hospital of Southern Medical University /ID# 260558 | Active, not recruiting | Guangzhou | Guangdong | 510280 | China |
| Nanfang Hospital of Southern Medical University /ID# 260795 | Active, not recruiting | Guangzhou | Guangdong | 510515 | China |
| Shenzhen People's Hospital /ID# 260137 | Recruiting | Shenzhen | Guangdong | 518020 | China |
| Affiliated Cancer Hospital of Guangxi Medical University /ID# 260537 | Active, not recruiting | Nanning | Guangxi | 530021 | China |
| People's Hospital of Henan Province /ID# 259619 | Recruiting | Zhengzhou | Henan | 450003 | China |
| Henan Cancer Hospital /ID# 259618 | Active, not recruiting | Zhengzhou | Henan | 450008 | China |
| Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 259743 | Recruiting | Wuhan | Hubei | 430048 | China |
| Hubei Cancer Hospital /ID# 260506 | Recruiting | Wuhan | Hubei | 430079 | China |
| Hunan Cancer Hospital /ID# 260439 | Recruiting | Changsha | Hunan | 410006 | China |
| The First Affiliated Hospital of Soochow University /ID# 260507 | Active, not recruiting | Suzhou | Jiangsu | 215006 | China |
| The First Affiliated Hospital of Nanchang University /ID# 260556 | Recruiting | Nanchang | Jiangxi | 330006 | China |
| Jiangxi Provincial Cancer Hospital /ID# 260559 | Completed | Nanchang | Jiangxi | 330029 | China |
| First Affiliated Hospital of China Medical University /ID# 260217 | Recruiting | Shenyang | Liaoning | 110001 | China |
| Shandong Cancer Hospital /ID# 260808 | Active, not recruiting | Jinan | Shandong | 251601 | China |
| Fudan University Shanghai Cancer Center /ID# 260564 | Recruiting | Shanghai | Shanghai Municipality | 200032 | China |
| West China Hospital, Sichuan University /ID# 260015 | Active, not recruiting | Chengdu | Sichuan | 610041 | China |
| Tianjin Cancer Hospital /ID# 259807 | Recruiting | Tianjin | Tianjin Municipality | 300000 | China |
| Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 259616 | Recruiting | Tianjin | Tianjin Municipality | 300020 | China |
| The Affiliated Cancer Hospital of Xinjiang Medical University /ID# 260644 | Recruiting | Ürümqi | Xinjiang | 830000 | China |
| Yunnan Cancer Hospital /ID# 260645 | Recruiting | Kunming | Yunnan | 650118 | China |
| The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 259744 | Active, not recruiting | Hangzhou | Zhejiang | 310003 | China |
| Zhejiang Cancer hospital /ID# 259742 | Active, not recruiting | Hangzhou | Zhejiang | 310022 | China |
| The First Affiliated Hospital of Wenzhou Medical University /ID# 260566 | Recruiting | Wenzhou | Zhejiang | 325000 | China |
| Clinical Hospital Dubrava /ID# 260452 | Completed | Zagreb | City of Zagreb | 10000 | Croatia |
| Klinicka bolnica Merkur /ID# 260393 | Completed | Zagreb | City of Zagreb | 10000 | Croatia |
| Klinicki bolnicki centar Sestre milosrdnice /ID# 260456 | Completed | Zagreb | City of Zagreb | 10000 | Croatia |
| Klinicki bolnicki centar Zagreb /ID# 260364 | Active, not recruiting | Zagreb | City of Zagreb | 10000 | Croatia |
| Klinicki bolnicki centar Rijeka /ID# 260455 | Active, not recruiting | Rijeka | Primorje-Gorski Kotar County | 51000 | Croatia |
| Klinicki Bolnicki Centar (KBC) Split /ID# 260454 | Active, not recruiting | Split | Split-Dalmatia County | 21000 | Croatia |
| Zadar General Hospital /ID# 260837 | Completed | Zadar | 23000 | Croatia |
| Fakultni Nemocnice Brno - Jihlavska /ID# 260571 | Active, not recruiting | Brno | Brno-mesto | 625 00 | Czechia |
| Fakultni nemocnice Hradec Kralove - Sokolska /ID# 260560 | Active, not recruiting | Hradec Králové | 500 05 | Czechia |
| Fakultni nemocnice Kralovske Vinohrady /ID# 260572 | Active, not recruiting | Prague | 100 34 | Czechia |
| Rigshospitalet /ID# 260779 | Active, not recruiting | Copenhagen Ø | Capital Region | 2100 | Denmark |
| Regionshospitalet Godstrup /ID# 260778 | Completed | Herning | Central Jutland | 7400 | Denmark |
| Roskilde Sygehus /ID# 260780 | Active, not recruiting | Roskilde | Region Sjælland | 4000 | Denmark |
| Odense University Hospital /ID# 260777 | Active, not recruiting | Odense | Region Syddanmark | 5000 | Denmark |
| Vejle Sygehus /ID# 260781 | Active, not recruiting | Vejle | Region Syddanmark | 7100 | Denmark |
| CHU de CAEN - Hopital de la Cote de Nacre /ID# 260875 | Recruiting | Caen | Calvados | 14033 | France |
| CHU Brest - Hopital de la Cavale Blanche /ID# 260601 | Recruiting | Brest | Finistere | 29200 | France |
| Hopital Prive du Confluent /ID# 260596 | Recruiting | Nantes | Loire-Atlantique | 44277 | France |
| Centre Hospitalier D'Avignon /ID# 260511 | Recruiting | Avignon | Provence-Alpes-Côte d'Azur Region | 84000 | France |
| HCL - Hopital Lyon Sud /ID# 260508 | Recruiting | Pierre-Bénite | Rhone | 69495 | France |
| Centre Hospitalier du Mans /ID# 260510 | Recruiting | Le Mans | Sarthe | 72037 | France |
| CH Libourne - Hopital Robert Boulin /ID# 261478 | Recruiting | Libourne | 33500 | France |
| Hopital Saint-Louis /ID# 260509 | Recruiting | Paris | 75010 | France |
| Clinique Sainte-Anne /ID# 261528 | Completed | Strasbourg | 67085 | France |
| Hopital Prive d'Antony /ID# 260598 | Recruiting | Antony | Île-de-France Region | 92160 | France |
| Staedtisches Klinikum Karlsruhe /ID# 260348 | Active, not recruiting | Karlsruhe | Baden-Wurttemberg | 76133 | Germany |
| Universitaetsklinikum Frankfurt /ID# 260388 | Active, not recruiting | Frankfurt am Main | Hesse | 60590 | Germany |
| Klinikum Kassel /ID# 260432 | Active, not recruiting | Kassel | Hesse | 34125 | Germany |
| St.-Antonius-Hospital /ID# 260520 | Completed | Eschweiler | North Rhine-Westphalia | 52249 | Germany |
| Klinikum Ludwigshafen /ID# 260688 | Active, not recruiting | Ludwigshafen am Rhein | Rhineland-Palatinate | 67063 | Germany |
| Otto-von-Guericke-Universitaet /ID# 260425 | Active, not recruiting | Magdeburg | Saxony-Anhalt | 39120 | Germany |
| Olympion General Clinic /ID# 262395 | Active, not recruiting | Pátrai | Achaia | 26443 | Greece |
| General Hospital of Athens Laiko /ID# 259708 | Active, not recruiting | Athens | Attica | 11527 | Greece |
| University General Hospital Attikon /ID# 260855 | Active, not recruiting | Chaïdári | Attica | 12462 | Greece |
| General University Hospital of Alexandroupolis /ID# 260858 | Active, not recruiting | Alexandroupoli | 68100 | Greece |
| General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 259709 | Active, not recruiting | Athens | 10676 | Greece |
| Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 260051 | Completed | Győr | Győr-Moson-Sopron | 9024 | Hungary |
| Tolna Varmegyei Balassa Janos Korhaz /ID# 260048 | Active, not recruiting | Szekszárd | Tolna County | 7100 | Hungary |
| Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 260050 | Recruiting | Szombathely | Vas County | 9700 | Hungary |
| Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet /ID# 260049 | Completed | Budapest | 1097 | Hungary |
| Orszagos Onkologiai Intezet /ID# 260052 | Active, not recruiting | Budapest | 1122 | Hungary |
| Meir Medical Center /ID# 259938 | Recruiting | Kfar Saba | Central District | 4428164 | Israel |
| Rabin Medical Center. /ID# 268328 | Recruiting | Petah Tikva | Central District | 4941492 | Israel |
| HaEmek Medical Center /ID# 259936 | Recruiting | Afula | Haifa District | 1834111 | Israel |
| Hadassah /ID# 259935 | Recruiting | Jerusalem | Jerusalem | 91120 | Israel |
| Soroka University Medical Center /ID# 259937 | Recruiting | Beersheba | Southern District | 8443901 | Israel |
| The Chaim Sheba Medical Center /ID# 259934 | Recruiting | Ramat Gan | Tel Aviv | 5265601 | Israel |
| Tel Aviv Sourasky Medical Center /ID# 259933 | Recruiting | Tel Aviv | Tel Aviv | 6423906 | Israel |
| IRCCS Istituto Clinico Humanitas /ID# 260887 | Active, not recruiting | Rozzano | Lombardy | 20089 | Italy |
| Istituto di Candiolo Fondazione del Piemonte per l'Oncologia IRCCS /ID# 260889 | Active, not recruiting | Candiolo | Torino | 10060 | Italy |
| IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 260886 | Active, not recruiting | Bologna | 40138 | Italy |
| AOU Policlinico G. Rodolico - San Marco /ID# 260890 | Active, not recruiting | Catania | 95123 | Italy |
| Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello /ID# 260888 | Active, not recruiting | Palermo | 90146 | Italy |
| AUSL di Reggio Emilia - Arcispedale Santa Maria Nuova /ID# 260744 | Active, not recruiting | Reggio Emilia | 42122 | Italy |
| Fondazione Policlinico Universitario Campus Bio-Medico /ID# 260891 | Active, not recruiting | Roma | 00128 | Italy |
| Fujita Health University Hospital /ID# 264679 | Active, not recruiting | Toyoake | Aichi-ken | 470-1192 | Japan |
| Matsuyama Red Cross Hospital /ID# 266426 | Active, not recruiting | Matsuyama | Ehime | 790-8524 | Japan |
| University of Fukui Hospital /ID# 265680 | Active, not recruiting | Yoshida-gun | Fukui | 910-1104 | Japan |
| National Hospital Organization Kyushu Cancer Center /ID# 265960 | Recruiting | Fukuoka | Fukuoka | 811-1395 | Japan |
| Kyushu University Hospital /ID# 267861 | Recruiting | Fukuoka | Fukuoka | 812-8582 | Japan |
| Fukushima Medical University Hospital /ID# 264994 | Active, not recruiting | Fukushima | Fukushima | 960-1295 | Japan |
| Chugoku Central Hospital /ID# 266520 | Active, not recruiting | Fukuyama | Hiroshima | 720-0001 | Japan |
| Sapporo Medical University Hospital /ID# 265031 | Active, not recruiting | Sapporo | Hokkaido | 060-8543 | Japan |
| Kobe City Medical Center General Hospital /ID# 266379 | Completed | Kobe | Hyōgo | 650-0047 | Japan |
| Hitachi General Hospital /ID# 265676 | Recruiting | Hitachi-shi | Ibaraki | 317-0077 | Japan |
| Kitasato University Hospital /ID# 264675 | Active, not recruiting | Sagamihara-shi | Kanagawa | 252-0375 | Japan |
| Kanagawa Cancer Center /ID# 265497 | Recruiting | Yokohama | Kanagawa | 241-8515 | Japan |
| Okayama University Hospital /ID# 267135 | Completed | Okayama | Okayama-ken | 700-8558 | Japan |
| Kansai Medical University Hospital /ID# 266019 | Recruiting | Hirakata-shi | Osaka | 573-1191 | Japan |
| Kindai University Hospital /ID# 265038 | Recruiting | Sakai-shi | Osaka | 590-0197 | Japan |
| Tokyo Metropolitan Komagome Hospital /ID# 267692 | Recruiting | Bunkyo Ku | Tokyo | 113-8677 | Japan |
| The University of Tokyo Hospital /ID# 266422 | Recruiting | Bunkyo-ku | Tokyo | 113-8654 | Japan |
| Yamaguchi University Hospital /ID# 265619 | Active, not recruiting | Ube | Yamaguchi | 755-8505 | Japan |
| University of Yamanashi Hospital /ID# 264677 | Active, not recruiting | Chuo-shi | Yamanashi | 409-3898 | Japan |
| Aomori Prefectural Central Hospital /ID# 265692 | Recruiting | Aomori | 030-0913 | Japan |
| Chiba Cancer Center /ID# 267316 | Completed | Chiba | 260-0801 | Japan |
| Bravis Ziekenhuis /ID# 259055 | Completed | Roosendaal | North Brabant | 4708 AE | Netherlands |
| Elisabeth Tweesteden Ziekenhuis /ID# 261239 | Completed | Tilburg | North Brabant | 5022 GC | Netherlands |
| Olvg /Id# 259543 | Completed | Amsterdam | North Holland | 1091 AC | Netherlands |
| Leids Universitair Medisch Centrum /ID# 259049 | Active, not recruiting | Leiden | South Holland | 2333 ZA | Netherlands |
| Franciscus Gasthuis & Vlietland, Locatie Gasthuis /ID# 259052 | Active, not recruiting | Rotterdam | South Holland | 3045 PM | Netherlands |
| HagaZiekenhuis /ID# 261220 | Active, not recruiting | The Hague | South Holland | 2545 AA | Netherlands |
| St. Antonius Ziekenhuis /ID# 259053 | Active, not recruiting | Nieuwegein | Utrecht | 3435 CM | Netherlands |
| Rijnstate /ID# 261219 | Completed | Arnhem | 6815 AD | Netherlands |
| Universitair Medisch Centrum Groningen /ID# 259051 | Active, not recruiting | Groningen | 9713 GZ | Netherlands |
| Auckland City Hospital /ID# 259330 | Recruiting | Grafton | Auckland | 1023 | New Zealand |
| North Shore Hospital /ID# 260824 | Recruiting | Takapuna | Auckland | 0622 | New Zealand |
| Aidport sp z o.o. /ID# 267717 | Active, not recruiting | Poznan | Greater Poland Voivodeship | 60-175 | Poland |
| Pratia MCM Krakow /ID# 260075 | Active, not recruiting | Krakow | Lesser Poland Voivodeship | 30-727 | Poland |
| Narodowy Instytut Onkologii im. M. Sklodowskiej /ID# 260861 | Active, not recruiting | Warsaw | Masovian Voivodeship | 02-781 | Poland |
| Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopern /ID# 260633 | Active, not recruiting | Lodz | Łódź Voivodeship | 93-513 | Poland |
| Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 260170 | Active, not recruiting | Kielce | Świętokrzyskie Voivodeship | 25-734 | Poland |
| Fundacao Champalimaud /ID# 259652 | Active, not recruiting | Lisbon | Lisbon District | 1400-038 | Portugal |
| Unidade Local de Saude de Gaia/Espinho /ID# 259655 | Active, not recruiting | Vila Nova de Gaia | Porto District | 4434-502 | Portugal |
| Unidade Local de Saude de Santa Maria /ID# 259650 | Active, not recruiting | Lisbon | 1649-035 | Portugal |
| Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 259649 | Active, not recruiting | Porto | 4200-072 | Portugal |
| Pan American Center for Oncology Trials, LLC /ID# 260265 | Active, not recruiting | Rio Piedras | 00935 | Puerto Rico |
| Auxilio Mutuo Cancer Center /ID# 260262 | Recruiting | San Juan | 00918 | Puerto Rico |
|
| Fundeni Clinical Institute /ID# 260296 | Active, not recruiting | Bucharest | Bucharest | 022328 | Romania |
| Institutul Oncologic Prof Dr. Ion Chiricuta Cluj Napoca /ID# 259704 | Active, not recruiting | Cluj-Napoca | Cluj | 400015 | Romania |
| Institutul Regional de Oncologie /ID# 259697 | Active, not recruiting | Iași | Iaşi | 700483 | Romania |
| Spitalul Clinic Coltea /ID# 259699 | Active, not recruiting | Bucharest | 030171 | Romania |
| Clinical Hospital Center Zvezdara /ID# 260900 | Active, not recruiting | Belgrade | Beograd | 11000 | Serbia |
| University Clinical Center Serbia /ID# 259271 | Active, not recruiting | Belgrade | Beograd | 11000 | Serbia |
| University Clinical Center Kragujevac /ID# 259274 | Active, not recruiting | Kragujevac | Sumadijski Okrug | 34000 | Serbia |
| Institute for Oncology of Vojvodina /ID# 260223 | Active, not recruiting | Kamenitz | Vojvodina | 21208 | Serbia |
| University Clinical Center Vojvodina /ID# 259272 | Active, not recruiting | Novi Sad | 21000 | Serbia |
| Narodny onkologicky ustav /ID# 260638 | Active, not recruiting | Bratislava | Bratislava Region | 833 10 | Slovakia |
| Univerzitna nemocnica Martin /ID# 260631 | Completed | Martin | Žilina Region | 036 01 | Slovakia |
| Wits Clinical Research /ID# 260958 | Recruiting | Johannesburg | Gauteng | 1864 | South Africa |
| Alberts Cellular Therapy /ID# 260514 | Recruiting | Pretoria | Gauteng | 0044 | South Africa |
| Haemalife Inc. /ID# 260513 | Recruiting | Kuils River | Western Cape | 7580 | South Africa |
| Seoul National University Bundang Hospital /ID# 260009 | Active, not recruiting | Seongnam-si | Gyeonggido | 13620 | South Korea |
| Seoul National University Hospital /ID# 260007 | Active, not recruiting | Seoul | Seoul Teugbyeolsi | 03080 | South Korea |
| Asan Medical Center /ID# 260010 | Recruiting | Seoul | Seoul Teugbyeolsi | 05505 | South Korea |
| Samsung Medical Center /ID# 260008 | Active, not recruiting | Seoul | Seoul Teugbyeolsi | 06351 | South Korea |
| Instituto Catalan de Oncologia (ICO) Badalona /ID# 260495 | Active, not recruiting | Badalona | Barcelona | 08916 | Spain |
| Institut Catala dOncologia - LHospitalet /ID# 261439 | Active, not recruiting | L'Hospitalet de Llobregat | Barcelona | 08907 | Spain |
| Hospital Universitario Marques de Valdecilla /ID# 260497 | Active, not recruiting | Santander | Cantabria | 39008 | Spain |
| Clinica Universidad de Navarra - Pamplona /ID# 260496 | Active, not recruiting | Pamplona | Navarre | 31008 | Spain |
| Hospital Universitario Vall de Hebron /ID# 260490 | Active, not recruiting | Barcelona | 08035 | Spain |
| Hospital Clinic de Barcelona /ID# 260492 | Active, not recruiting | Barcelona | 08036 | Spain |
| Hospital Santa Creu i Sant Pau /ID# 260498 | Active, not recruiting | Barcelona | 08041 | Spain |
| Hospital San Pedro de Alcantara /ID# 260502 | Active, not recruiting | Cáceres | 10003 | Spain |
| CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 261512 | Active, not recruiting | Madrid | 28027 | Spain |
| MD Anderson Madrid /ID# 260500 | Active, not recruiting | Madrid | 28033 | Spain |
| Hospital Universitario de Salamanca /ID# 260491 | Active, not recruiting | Salamanca | 37711 | Spain |
| Sodra Alvsborgs sjukhus /ID# 261168 | Completed | Borås | Västra Götaland County | 501 82 | Sweden |
| Sahlgrenska Universitetssjukhuset /ID# 266600 | Completed | Gothenburg | Västra Götaland County | 413 46 | Sweden |
| China Medical University Hospital /ID# 260357 | Active, not recruiting | Taichung | 40447 | Taiwan |
| Taichung Veterans General Hospital /ID# 260361 | Active, not recruiting | Taichung | 40705 | Taiwan |
| National Cheng Kung University Hospital /ID# 260363 | Active, not recruiting | Tainan | 704 | Taiwan |
| National Taiwan University Hospital /ID# 260341 | Active, not recruiting | Taipei | 100 | Taiwan |
| Istanbul Florence Nightingale Hospital /ID# 271291 | Recruiting | Şişli | Istanbul | 34381 | Turkey (Türkiye) |
| Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 259804 | Recruiting | Istanbul | 34899 | Turkey (Türkiye) |
| Ege Universitesi Tip Fakultesi /ID# 259803 | Recruiting | Izmir | 35100 | Turkey (Türkiye) |
| Kocaeli University Med Faculty /ID# 259717 | Recruiting | Kocaeli | 41380 | Turkey (Türkiye) |
| Ondokuz Mayis Universitesi /ID# 259713 | Recruiting | Samsun | 55139 | Turkey (Türkiye) |
| University Hospitals Plymouth NHS Trust /ID# 262671 | Recruiting | Plymouth | Devon | PL6 8DH | United Kingdom |
| Hammersmith Hospital /ID# 261124 | Recruiting | London | England | W12 0HS | United Kingdom |
| Queen Alexandra Hospital /ID# 269708 | Recruiting | Portsmouth | Hampshire | PO6 3LY | United Kingdom |
| Leeds Teaching Hospitals NHS Trust /ID# 260466 | Recruiting | Leeds | West Yorkshire | LS9 7TF | United Kingdom |
| The Christie Hospital /ID# 260463 | Recruiting | Manchester | M20 4BX | United Kingdom |
| The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 260792 | Recruiting | Newcastle upon Tyne | NE3 3HD | United Kingdom |
| ID | Term |
|---|---|
| D008224 | Lymphoma, Follicular |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D011241 | Prednisone |
| D000069283 | Rituximab |
| D000077269 | Lenalidomide |
| D004317 | Doxorubicin |
| D014750 | Vincristine |
| D003520 | Cyclophosphamide |
| C543332 | obinutuzumab |
| D000069461 | Bendamustine Hydrochloride |
| ID | Term |
|---|---|
| D011244 | Pregnadienediols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D058846 | Antibodies, Monoclonal, Murine-Derived |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D010797 | Phthalimides |
| D010795 | Phthalic Acids |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D010881 | Piperidones |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D054833 | Isoindoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D003630 | Daunorubicin |
| D018943 | Anthracyclines |
| D009279 | Naphthacenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D000617 | Aminoglycosides |
| D006027 | Glycosides |
| D002241 | Carbohydrates |
| D014748 | Vinca Alkaloids |
| D046948 | Secologanin Tryptamine Alkaloids |
| D026121 | Indole Alkaloids |
| D000470 | Alkaloids |
| D007211 | Indoles |
| D054836 | Indolizidines |
| D007212 | Indolizines |
| D010752 | Phosphoramide Mustards |
| D009588 | Nitrogen Mustard Compounds |
| D009150 | Mustard Compounds |
| D006846 | Hydrocarbons, Halogenated |
| D063088 | Phosphoramides |
| D009943 | Organophosphorus Compounds |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
| D001562 | Benzimidazoles |
Not provided
Not provided